Study guide
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality
Key Takeaways Explain This Topic AI
Dipotassium EDTA (K2EDTA) spray-dried at 1.5 to 2.2 mg/mL is the ICSH and CLSI reference anticoagulant for routine hematology; tripotassium EDTA (K3EDTA) liquid causes a 1% to 2% osmotic dilution and pronounced red cell shrinkage upon underfilling.
Underfilling EDTA tubes produces an excessive anticoagulant-to-blood ratio, inducing hypertonic osmotic erythrocyte shrinkage, falsely decreased hematocrit and MCV, falsely elevated MCHC, and falsely depressed ESR.
For coagulation assays, 3.2% (0.109 M) buffered sodium citrate requires a strict 9:1 blood-to-anticoagulant ratio; in polycythemic patients with hematocrit > 55%, excess plasma citrate must be adjusted using C = 1.85 x 10^-3 x (100 - Hct) x V_blood to avoid falsely prolonged PT and aPTT.
EDTA-dependent pseudothrombocytopenia is caused by in vitro autoantibodies directed against cryptic GP IIb/IIIa epitopes exposed upon calcium chelation; it is resolved by redrawing the specimen in 3.2% sodium citrate and multiplying the automated platelet count by a 1.1 dilution correction factor.
Peripheral blood smears should be prepared within 2 to 4 hours of venipuncture; unpreserved storage beyond 4 hours induces red cell crenation, leukocyte nuclear pyknosis, cytoplasmic vacuolation in monocytes and neutrophils, and necrobiosis.
Last updated: October 2026
Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality
In clinical hematology, analytical accuracy depends entirely on specimen integrity. Up to 70% of all diagnostic laboratory errors occur during the preanalytical phase —encompassing patient preparation, venipuncture technique, anticoagulant selection, tube filling volume, specimen mixing, transport, and storage. Because modern hematology analyzers measure subtle cellular volumes down to fractions of a femtoliter ( 10 − 15 L 10^{-15}\text{ L} 1 0 − 15 L ) and evaluate delicate optical scatter patterns, minor preanalytical deviations produce profound diagnostic errors, misclassifying anemias, falsely triggering acute leukemia flags, or masking severe thrombocytopenia. ┌────────────────────────────────────────────────────────┐
- │ Hematology Specimen Collection & Anticoagulant Tree │
- └───────────────────────────┬────────────────────────────┘
- │
- ┌───────────────────────────┴───────────────────────────┐
- ▼ ▼
- ┌───────────────────────────────┐ ┌───────────────────────────────┐
- │ Lavender Top: EDTA Tube │ │ Light Blue: Sodium Citrate │
- │ (Routine CBC, Indices, Smear)│ │ (Coagulation: PT, aPTT, TT) │
- └───────────────┬───────────────┘ └───────────────┬───────────────┘
- │ │
- ┌───────────────┴───────────────┐ ┌───────────────┴───────────────┐
- ▼ ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │Spray-Dried │ │ Liquid │ │ Strict 9:1 │ │ Hct > 55% │
- │K2EDTA (ICSH) │ │ K3EDTA │ │ Whole Blood │ │ Polycythemia │
- │1.5-2.2 mg/mL │ │1-2% Dilution │ │ to Citrate │ │ Correction │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │ │
- Preserves RBC volume • Shrinks RBCs • 3.2% (0.109 M) • C = 1.85 x 10^-3
- Best for cell sizing • Underfill = artifact buffered citrate x (100 - Hct) x V
- Chelation of Ca2+ • Chelation of Ca2+ • Underfill = ↑ PT/aPTT • Prevents false ↑ PT
- 1. Hematology Anticoagulants: EDTA Formulations and Mechanics
Ethylenediaminetetraacetic acid (EDTA) is the universally accepted anticoagulant for routine Complete Blood Counts (CBC), erythrocyte indices, and peripheral blood smear evaluations.
Biochemical Mechanism of Action
EDTA functions by chelating divalent ionized calcium ( C a 2 + Ca^{2+} C a 2 + ), forming a stable, non-ionizable soluble complex. Because calcium is an indispensable cofactor (Factor IV) in the intrinsic, extrinsic, and common coagulation cascades—required for the activation of Factor IX, Factor X, and prothrombin conversion to thrombin—its removal halts the clotting cascade at its earliest stages. Simultaneously, calcium chelation suppresses calcium-dependent platelet activation and aggregation, maintaining erythrocytes, leukocytes, and platelets in an unaggregated, free-floating suspension.
Chemical Formulations: K 2 EDTA K_2\text{EDTA} K 2 EDTA vs. K 3 EDTA K_3\text{EDTA} K 3 EDTA vs. N a 2 EDTA Na_2\text{EDTA} N a 2 EDTA
Three primary formulations of EDTA have been utilized in vacutainer tubes, but their physiological and analytical behaviors differ substantially:
Dipotassium EDTA ( K 2 EDTA K_2\text{EDTA} K 2 EDTA ) :
Physical State : Spray-dried onto the interior glass or plastic tube walls.
Optimal Concentration : 1.5 to 2.2 mg 1.5\text{ to }2.2\text{ mg} 1.5 to 2.2 mg per milliliter of whole blood (the ICSH range, about 3.4 to 5.0 mmol/L 3.4\text{ to }5.0\text{ mmol/L} 3.4 to 5.0 mmol/L ).
Clinical Recommendation : Recommended by both the International Council for Standardization in Haematology (ICSH) and the Clinical and Laboratory Standards Institute (CLSI) as the gold standard anticoagulant for automated hematology cell counting and sizing.
Analytical Advantage : Because it is spray-dried, it introduces zero liquid volume, avoiding any specimen dilution. Furthermore, K 2 EDTA K_2\text{EDTA} K 2 EDTA has a minimal hyperosmolar effect on erythrocytes, preserving true Mean Corpuscular Volume ( M C V MCV MC V ) within 1 % 1\% 1% of baseline for up to 24 hours.
Tripotassium EDTA ( K 3 EDTA K_3\text{EDTA} K 3 EDTA ) :
Physical State : Dispensed as a concentrated liquid solution.
Analytical Drawbacks : Liquid K 3 EDTA K_3\text{EDTA} K 3 EDTA causes an obligatory 1 % to 2 % 1\%\text{ to }2\% 1% to 2% dilutional decrease in all measured cellular concentrations (RBC count, WBC count, hemoglobin, and hematocrit). More significantly, tripotassium EDTA exerts an uncompensated hypertonic osmotic draw, pulling intracellular water out of erythrocytes. This produces progressive erythrocyte shrinkage, artifactually depressing the M C V MCV MC V by 2 % to 3 % 2\%\text{ to }3\% 2% to 3% compared to K 2 EDTA K_2\text{EDTA} K 2 EDTA .
Disodium EDTA ( N a 2 EDTA Na_2\text{EDTA} N a 2 EDTA ) :
Rarely used in modern clinical practice due to its poor water solubility, requiring prolonged dissolution times that risk partial microclot formation.
Analytical Effects of Tube Underfilling
Underfilling an EDTA tube (collecting less than 80 % 80\% 80% of the nominal fill volume) produces an abnormally high concentration of EDTA relative to blood volume:
Erythrocyte Shrinkage : High EDTA concentration creates a hypertonic extracellular plasma environment. Free water exits the red cells via osmosis, causing cellular dehydration and shrinkage.
Falsely Decreased MCV and Hematocrit : Automated cell counters measure smaller voltage or light scatter pulses, reducing the measured M C V MCV MC V . Because automated hematocrit is calculated as ( RBC × MCV ) / 10 (\text{RBC} \times \text{MCV}) / 10 ( RBC × MCV ) /10 , hematocrit drops artifactually.
Falsely Elevated MCHC : Since cellular hemoglobin mass remains constant while the measured red cell volume decreases, the calculated Mean Corpuscular Hemoglobin Concentration ( MCHC = [ Hb / Hct ] × 100 \text{MCHC} = [\text{Hb} / \text{Hct}] \times 100 MCHC = [ Hb / Hct ] × 100 ) increases, often exceeding the physiological threshold of 36.0 g/dL 36.0\text{ g/dL} 36.0 g/dL .
Falsely Decreased ESR : Hypertonic cell shrinkage and altered membrane charge prevent erythrocytes from stacking into rouleaux columns, leading to a markedly depressed Erythrocyte Sedimentation Rate.
Platelet Swelling and Disintegration : Excess EDTA induces progressive platelet ballooning, fragmentation, and disintegration into microparticles that can be erroneously registered as microcytic erythrocytes or background noise.
Analytical Effects of Tube Overfilling
Overfilling occurs when vacuum tubes are forced beyond their intended capacity or when blood is transferred from a syringe without respecting the fill line:
Inadequate Anticoagulation : Insufficient EDTA concentration allows trace thrombin generation.
Fibrin Microclots : Incomplete anticoagulation generates microscopic fibrin strands that entrap platelets and leukocytes.
Pseudothrombocytopenia and Pseudoleukopenia : Platelets and white blood cells consumed within microclots are excluded from automated counts, yielding dangerously false thrombocytopenia and leukopenia.
Aperture Clogging : Microclots obstruct analyzer hydraulic chambers and counting orifices, triggering recurrent sensor error flags.
2. Sodium Citrate (3.2%, 0.109 M) and Coagulation Specimen Quality
While EDTA is optimal for cell morphology, it irreversibly denatures coagulation Factors V and VIII and binds calcium so tightly that it cannot be consistently overcome by calcium re-addition. Therefore, buffered sodium citrate is the mandatory anticoagulant for coagulation diagnostics. ┌────────────────────────────────────────────────────────┐
- │ Sodium Citrate Tube Mechanics (9:1 Whole Blood/AC) │
- └───────────────────────────┬────────────────────────────┘
- │
- ┌──────────────────────────────┴──────────────────────────────┐
- ▼ ▼
- ┌───────────────────────────────┐ ┌───────────────────────────────┐
- │ Normal Patient (Hct 40%) │ │ Polycythemic Patient (Hct 65%)│
- ├───────────────────────────────┤ ├───────────────────────────────┤
- │ Total Blood Draw: 4.5 mL │ │ Total Blood Draw: 4.5 mL │
- │ • Plasma Volume: 2.7 mL │ │ • Plasma Volume: 1.575 mL │
- │ • Citrate Volume: 0.5 mL │ │ • Citrate Volume: 0.5 mL │
- │ • Ratio: Citrate / Plasma OK │ │ • Ratio: Citrate / Plasma ↑↑ │
- └──────────────┬────────────────┘ └──────────────┬────────────────┘
- │ │
- ▼ ▼
- ┌───────────────────────────────┐ ┌───────────────────────────────┐
- │ Calcium in PT/aPTT Reagent │ │ Excess Unchelated Citrate │
- │ Overcomes Citrate Exactly │ │ Neutralizes Reagent Calcium │
- ├───────────────────────────────┤ ├───────────────────────────────┤
- │ Result: Accurate Clot Times │ │ Result: Falsely Prolonged PT │
- └───────────────────────────────┘ └───────────────────────────────┘
- Standard 9:1 Blood-to-Anticoagulant Ratio
Per CLSI guideline H21-A5, coagulation testing requires 3.2% (0.109 mol/L) buffered sodium citrate . The liquid anticoagulant must maintain an exact ratio of 9 parts whole blood to 1 part anticoagulant (e.g., 4.5 mL 4.5\text{ mL} 4.5 mL blood added to 0.5 mL 0.5\text{ mL} 0.5 mL citrate, or 2.7 mL 2.7\text{ mL} 2.7 mL blood to 0.3 mL 0.3\text{ mL} 0.3 mL citrate, yielding a 10 % 10\% 10% anticoagulant fraction by total volume).
Mechanism of Underfilling in Citrate Tubes
Underfilling a citrate tube is one of the most common causes of specimen rejection in the clinical laboratory:
If a tube is filled to only half its intended volume, the ratio of liquid citrate to blood becomes excessive ( 4 : 1 4:1 4 : 1 or 5 : 1 5:1 5 : 1 instead of 9 : 1 9:1 9 : 1 ).
The excess, unchelated citrate remains dissolved in the patient's plasma.
During automated Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) testing, a standardized, fixed concentration of calcium chloride ( 0.025 M C a C l 2 0.025\text{ M } CaCl_2 0.025 M C a C l 2 ) is added to initiate clotting.
The surplus free citrate in the patient's plasma rapidly chelates the reagent's added calcium.
Fibrin polymerization is markedly delayed, producing falsely prolonged PT and aPTT results , which may prompt inappropriate administration of fresh frozen plasma or withholding of critical anticoagulation therapy.
Hematocrit Correction for Polycythemic Patients
The 9:1 whole blood-to-citrate ratio is calibrated for individuals with normal hematocrits ( 35 % to 45 % 35\%\text{ to }45\% 35% to 45% ). Coagulation factors reside exclusively in the plasma fraction , not in erythrocytes.
When a patient has extreme erythrocytosis or polycythemia with a hematocrit exceeding 55% , the relative plasma volume per milliliter of whole blood is sharply reduced. Consequently, a standard volume of 3.2% citrate provides an overwhelming excess of anticoagulant relative to the small plasma volume. This excess citrate chelates the testing reagent calcium, causing falsely prolonged clotting times.
To prevent this, the volume of sodium citrate in the collection tube must be mathematically adjusted prior to phlebotomy using the standardized CLSI formula:
C = 1.85 × 10 − 3 × ( 100 − Hct ) × V blood C = 1.85 \times 10^{-3} \times (100 - \text{Hct}) \times V_{\text{blood}} C = 1.85 × 1 0 − 3 × ( 100 − Hct ) × V blood
Alternatively written as: C = 0.00185 × ( 100 − Hct ) × V blood \text{Alternatively written as: } C = 0.00185 \times (100 - \text{Hct}) \times V_{\text{blood}} Alternatively written as: C = 0.00185 × ( 100 − Hct ) × V blood
Where:
- C C C = Volume of 3.2% sodium citrate remaining in the tube (in mL \text{mL} mL )
- Hct \text{Hct} Hct = Patient's hematocrit (expressed as a whole percentage, e.g., 65)
- V blood V_{\text{blood}} V blood = Volume of whole blood to be added to the tube (in mL \text{mL} mL )
Step-by-Step Clinical Calculation:
A polycythemic patient with a hematocrit of 65 % 65\% 65% requires PT and aPTT monitoring. The laboratory utilizes standard 5.0 mL 5.0\text{ mL} 5.0 mL draw tubes that normally contain 0.5 mL 0.5\text{ mL} 0.5 mL of citrate and require 4.5 mL 4.5\text{ mL} 4.5 mL of blood ( V blood = 4.5 mL V_{\text{blood}} = 4.5\text{ mL} V blood = 4.5 mL ):
Substitute values into the equation: C = 0.00185 × ( 100 − 65 ) × 4.5 C = 0.00185 \times (100 - 65) \times 4.5 C = 0.00185 × ( 100 − 65 ) × 4.5
Perform arithmetic: C = 0.00185 × 35 × 4.5 = 0.06475 × 4.5 = 0.291 mL C = 0.00185 \times 35 \times 4.5 = 0.06475 \times 4.5 = 0.291\text{ mL} C = 0.00185 × 35 × 4.5 = 0.06475 × 4.5 = 0.291 mL
Laboratory Action : The technologist opens a standard tube containing 0.50 mL 0.50\text{ mL} 0.50 mL of citrate, aspirates and discards 0.21 mL 0.21\text{ mL} 0.21 mL ( 0.50 − 0.29 = 0.21 mL 0.50 - 0.29 = 0.21\text{ mL} 0.50 − 0.29 = 0.21 mL ), leaving exactly 0.29 mL 0.29\text{ mL} 0.29 mL of citrate in the tube. The phlebotomist then draws exactly 4.5 mL 4.5\text{ mL} 4.5 mL of whole blood into this adjusted tube, completely eliminating the preanalytical artifact.
3. Preanalytical Artifacts: EDTA-Dependent Pseudothrombocytopenia
EDTA-dependent pseudothrombocytopenia is a benign, in vitro phenomenon occurring in approximately 0.1 % to 0.2 % 0.1\%\text{ to }0.2\% 0.1% to 0.2% of the general population and up to 2 % 2\% 2% of hospitalized inpatients. EDTA-Dependent Pseudothrombocytopenia Pathophysiological Cascade:
- ┌────────────────────────────────────────────────────────────────────────┐
- │ Normal In Vivo Platelet: GP IIb/IIIa (αIIbβ3) requires Ca2+ for shape │
- └───────────────────────────────────┬────────────────────────────────────┘
- │
- ▼ Blood drawn into EDTA
- ┌────────────────────────────────────────────────────────────────────────┐
- │ EDTA chelates ionized Ca2+ ──► Structural conformational change │
- │ Dissociation of GP IIb/IIIa exposes cryptic "hidden" neo-epitopes │
- └───────────────────────────────────┬────────────────────────────────────┘
- │
- ▼ In vitro reaction
- ┌────────────────────────────────────────────────────────────────────────┐
- │ Patient's cold-reacting autoantibodies (IgG/IgM/IgA) bind neo-epitopes │
- │ Massive platelet agglutination + Satellitism around mature Neutrophils │
- └───────────────────────────────────┬────────────────────────────────────┘
- │
- ▼ Automated Analyzer Result
- ┌────────────────────────────────────────────────────────────────────────┐
- │ • Platelet clumps sized > 35 fL ──► Counted as Small Lymphocytes │
- │ • Severe False Thrombocytopenia (e.g., PLT 12,000/µL) + False Lympho │
- └────────────────────────────────────────────────────────────────────────┘
- Immunological Mechanism and Platelet Satellitism
Under physiological in vivo conditions, platelet surface glycoprotein IIb/IIIa (integrin α I I b β 3 \alpha_{IIb}\beta_3 α II b β 3 ) is a calcium-dependent heterodimer essential for fibrinogen binding.
When whole blood is collected into EDTA, the rapid chelation of C a 2 + Ca^{2+} C a 2 + destabilizes the heterodimer complex, inducing a conformational change that exposes cryptic (normally hidden) peptide sequences on GP IIb.
In susceptible individuals, circulating cold-reacting autoantibodies—predominantly IgG , but occasionally IgM or IgA —directed against these cryptic epitopes bind to the altered receptors at room temperature ( 20 – 25 ∘ C 20\text{--}25^\circ\text{C} 20 – 2 5 ∘ C ).
The autoantibodies cross-link adjacent platelets, resulting in large, dense platelet agglutinates.
Simultaneously, the Fc portion of these platelet-bound antibodies binds to Fc γ \gamma γ RIII receptors on the surfaces of mature neutrophils and bands, producing platelet satellitism (satellitosis) , where rosettes of 4 to 20 platelets surround neutrophil membranes.
Analyzer Impact and Diagnostic Danger
Automated impedance and optical cell counters evaluate platelets within a strict electronic volume threshold (typically 2 to 20 fL 2\text{ to }20\text{ fL} 2 to 20 fL or 2 to 30 fL 2\text{ to }30\text{ fL} 2 to 30 fL ):
Platelet agglutinates composed of tens or hundreds of platelets possess aggregate volumes exceeding 35 to 50 fL 35\text{ to }50\text{ fL} 35 to 50 fL .
The analyzer excludes these clumps from the platelet aperture and misclassifies them as small lymphocytes or unlysed debris.
This produces a devastatingly false low platelet count (often < 20 , 000 / μ L < 20,000/\mu\text{L} < 20 , 000/ μ L ), accompanied by a subtle artifactual pseudolymphocytosis.
Unrecognized pseudothrombocytopenia has historically led to unnecessary bone marrow biopsies, high-dose corticosteroid therapy for misdiagnosed Immune Thrombocytopenia (ITP), and cancelled elective surgeries.
Standard Laboratory Resolution Protocol
When an unexplained low platelet count occurs, the technologist must execute the following corrective algorithm: Suspected Pseudothrombocytopenia Workflow:
- ┌────────────────────────────────────────────────────────┐
- │ 1. Examine Wright-stained peripheral blood smear │
- │ Confirm platelet clumps and/or neutrophil rosettes │
- └───────────────────────────┬────────────────────────────┘
- │
- ▼ Clumps Confirmed
- ┌────────────────────────────────────────────────────────┐
- │ 2. Order immediate redraw in 3.2% Sodium Citrate tube │
- │ (Alternative: Heparin or pre-warmed capillary smear)│
- └───────────────────────────┬────────────────────────────┘
- │
- ▼ Process on Analyzer
- ┌────────────────────────────────────────────────────────┐
- │ 3. Automated Platelet Count obtained on Citrate tube │
- │ Multiply result by 1.1 (Dilution Correction Factor) │
- └───────────────────────────┬────────────────────────────┘
- │
- ▼ Final Review
- ┌────────────────────────────────────────────────────────┐
- │ 4. Verify smear from citrate tube is clump-free │
- │ Report corrected count with technologist comment │
- └────────────────────────────────────────────────────────┘
Peripheral Blood Film Review : Always examine the feathered edge and lateral borders of a Wright-stained smear under low power ( 10 × 10\times 10 × ). Platelet clumps preferentially migrate to the smear perimeter.
Sodium Citrate Redraw : Collect a new blood specimen in a light blue-top tube containing 3.2% sodium citrate. Calcium is bound less aggressively, typically preventing the conformational change in GP IIb/IIIa.
Application of Dilution Factor : Because liquid sodium citrate dilutes whole blood by 10 % 10\% 10% (9 parts blood to 1 part anticoagulant), the automated platelet count generated from the citrate tube must be multiplied by a factor of 1.1 : True Platelet Count = Automated Citrate Platelet Count × 1.1 \text{True Platelet Count} = \text{Automated Citrate Platelet Count} \times 1.1 True Platelet Count = Automated Citrate Platelet Count × 1.1
Smear Verification : Check a smear prepared from the citrate tube to confirm complete dispersal of clumps.
Alternative Measures : If clumping persists in citrate, redraw in sodium heparin or collect an unanticoagulated capillary fingerstick blood smear for direct manual phase-contrast hemocytometer enumeration.
4. Specimen Stability, Smear Timing, and Storage Artifacts
Blood is a living tissue that undergoes ongoing metabolic activity, autolysis, and osmotic alteration following venipuncture.
The Critical Smear Preparation Window
CLSI guidelines mandate that peripheral blood smears be prepared within 2 to 4 hours of venipuncture . Storage beyond 4 hours at room temperature produces progressive morphological deterioration that invalidates differential counts. Time-Dependent Cellular Degeneration in Stored EDTA Blood:
- ┌──────────────────────────────────────────────────────────────────────────┐
- │ 0 to 2 Hours: Pristine morphology; sharp granules; normal RBC biconcavity│
- ├──────────────────────────────────────────────────────────────────────────┤
- │ 4 Hours: RBC crenation begins; minor neutrophil nuclear lobulation shifts │
- ├──────────────────────────────────────────────────────────────────────────┤
- │ 6 to 8 Hours: Neutrophil nuclear pyknosis (homogeneous dark spheres); │
- │ monocyte and neutrophil cytoplasmic vacuolation (pseudo-toxic change) │
- ├──────────────────────────────────────────────────────────────────────────┤
- │ > 12 to 24 Hours: Necrobiotic cells; cloverleaf nuclei; erythrocyte │
- │ spherocytosis; marked platelet swelling and automated MCV elevation │
- └──────────────────────────────────────────────────────────────────────────┘
- Morphological Artifacts in Stored EDTA Blood
Erythrocyte Alterations :
Echinocyte Formation (Crenation) : As intracellular ATP levels decline, the active extrusion of calcium ceases and lipid asymmetry in the cell membrane is lost, transforming normal biconcave discocytes into scalloped echinocytes featuring 10 to 30 blunt, regular surface spicules.
Osmotic Spherocytosis : With prolonged standing, the loss of selective membrane permeability causes erythrocytes to lose their central biconcave pallor and assume a spherical shape.
Leukocyte Alterations :
Nuclear Pyknosis and Karyorrhexis : Leukocyte nuclei condense into dense, structureless, intensely dark spheres (pyknosis) or fragment into multiple spherical apoptotic droplets (karyorrhexis). This can cause pyknotic neutrophils to be misidentified as nucleated red blood cells (orthochromic normoblasts).
Cytoplasmic Vacuolation : Neutrophils and monocytes develop prominent, clean-edged cytoplasmic vacuoles. In an unpreserved or delayed specimen, this is an in vitro artifact of autolysis, but it is frequently misdiagnosed as true toxic vacuolation secondary to severe sepsis.
Cloverleaf or Radial Nuclear Segmentation : Monocyte and lymphocyte nuclei undergo bizarre lobulation, folding into cloverleaf structures.
Smudge Cells / Necrobiotic Debris : Fragile degenerated leukocytes rupture during slide spreading, generating unclassifiable necrobiotic debris.
Platelet Artifacts :
Progressive degranulation and swelling, forming oversized, pale-staining giant platelets or disintegrating into particulate debris.
Storage Temperature and CBC Parameter Stability
When immediate testing is impossible, specimens must be handled according to temperature-dependent kinetics:
CBC / Hematology Parameter Stability at Room Temp ( 18 – 25 ∘ C 18\text{--}25^\circ\text{C} 18 – 2 5 ∘ C ) Stability Refrigerated ( 2 – 8 ∘ C 2\text{--}8^\circ\text{C} 2 – 8 ∘ C ) Primary Mechanism of Instability
Hemoglobin (Hb) Stable up to 24 to 48 hours Stable up to 72 hours Most stable parameter; iron remains bound within porphyrin rings
RBC Count Stable up to 24 hours Stable up to 48 hours Resistance of erythrocytes to spontaneous lysis
WBC Count Stable up to 24 hours Stable up to 48 hours Total count remains stable, but differential shifts rapidly
Platelet Count Stable up to 24 hours Stable up to 24 to 48 hours Platelet fragmentation or cold-induced clumping may alter count
Mean Corpuscular Volume (MCV) Unstable after 6 to 12 hours (sharp rise) Stable up to 24 hours Metabolic exhaustion of N a + / K + Na^+/K^+ N a + / K + ATPase pump allows water influx and cell swelling
Hematocrit (Hct) Unstable after 6 to 12 hours (rises with MCV) Stable up to 24 hours Calculated parameter directly dependent on MCV ( [ R B C × M C V ] / 10 [RBC \times MCV]/10 [ RBC × MC V ] /10 )
MCHC Unstable after 12 hours (drops) Stable up to 24 hours Decreases artifactually because calculated hematocrit rises while Hb is static
Erythrocyte Sedimentation Rate (ESR) Must be set up within 4 hours Stable up to 12 to 24 hours Cells lose discocyte shape, preventing rouleaux; must return to room temp before testing
Reticulocyte Count Stable up to 6 to 8 hours Stable up to 24 to 48 hours In vitro maturation of reticulocytes into mature RBCs consumes residual RNA
Blood Smear Morphology Must be made within 2 to 4 hours Unacceptable (causes cold clumping) Rapid degenerative nuclear pyknosis and false cytoplasmic vacuolation
5. Preanalytical Errors and Corrective Protocols Summary
Preanalytical Error / Condition Specific Tube / Additive Affected Primary Mechanism of Analytical Error Impact on Laboratory Results Mandatory Corrective Protocol
Underfilled EDTA Tube K 2 EDTA K_2\text{EDTA} K 2 EDTA / K 3 EDTA K_3\text{EDTA} K 3 EDTA (Lavender) Excessive anticoagulant concentration creates hypertonic plasma; osmotic water loss Falsely ↓ \downarrow ↓ MCV and Hct; falsely ↑ \uparrow ↑ MCHC; falsely ↓ \downarrow ↓ ESR Reject specimen; redraw tube filled to at least 80 % 80\% 80% nominal volume
Overfilled EDTA Tube K 2 EDTA K_2\text{EDTA} K 2 EDTA / K 3 EDTA K_3\text{EDTA} K 3 EDTA (Lavender) Insufficient EDTA allows localized thrombin generation and microclot formation Falsely ↓ \downarrow ↓ Platelet count; falsely ↓ \downarrow ↓ WBC count; instrument clogs Reject specimen; redraw respecting vacuum fill line; invert 8–10 times
Underfilled Citrate Tube 3.2% Sodium Citrate (Light Blue) Anticoagulant ratio exceeds 9 : 1 9:1 9 : 1 ; excess unchelated citrate binds reagent calcium Falsely ↑ \uparrow ↑ PT and aPTT (prolonged clotting times) Reject specimen; redraw with strict 9 : 1 9:1 9 : 1 whole blood-to-citrate ratio
Polycythemia ( Hct > 55 % \text{Hct} > 55\% Hct > 55% ) 3.2% Sodium Citrate (Light Blue) Decreased plasma volume per mL whole blood leaves excess free citrate Falsely ↑ \uparrow ↑ PT and aPTT (spurious bleeding diathesis) Adjust citrate volume using CLSI formula before collection; redraw
EDTA-Dependent Pseudothrombocytopenia K 2 EDTA K_2\text{EDTA} K 2 EDTA (Lavender) Cold-reacting autoantibodies bind cryptic GP IIb/IIIa epitopes exposed by C a 2 + Ca^{2+} C a 2 + chelation Severe false thrombocytopenia; pseudoleukocytosis; clumps on smear Redraw in 3.2% sodium citrate; multiply platelet count by 1.1; verify smear
Delayed Smear Preparation ( > 4 hr >4\text{ hr} > 4 hr ) EDTA Whole Blood Autolytic cellular decay; loss of membrane ATP; osmotic changes False toxic vacuolation; pyknotic WBCs; echinocytes; smudge cells Prepare wedge blood smears within 2 to 4 hours of collection
Vigorous Tube Agitation Any blood tube Mechanical shear stress ruptures erythrocyte and platelet membranes In vitro hemolysis; artifactual ↓ \downarrow ↓ RBC count; platelet debris Mix by gentle inversion 8 to 10 times; never shake or vortex vacutainers
Hemolyzed Specimen EDTA / Serum / Plasma Rupture of erythrocytes releases free hemoglobin and intracellular contents Falsely ↓ \downarrow ↓ RBC; discordant Rule of Three; interferes with optical sensors Reject for coagulation, blood bank, and chemistry; note hemolysis on CBC